PRESS RELEASE published on 09/12/2025 at 07:30, 7 months 19 days ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
BRIEF published on 09/10/2025 at 21:46, 7 months 21 days ago UZEDY® Obtains Approval in South Korea Following Success in the United States Schizophrenia UZEDY Teva Handok Medical Supply Korean Market
PRESS RELEASE published on 09/10/2025 at 21:41, 7 months 21 days ago Inside Information / Other news releases Teva Handok announces regulatory approval for UZEDY® in South Korea by Ministry of Food and Drug Safety, following successful US launch. Medincell's long-acting injectable for schizophrenia shows strong commercial performance Regulatory Approval Schizophrenia Medincell Commercial Performance Teva Handok
BRIEF published on 08/04/2025 at 14:05, 8 months 28 days ago Medincell Announces its 2025 General Meeting Governance General Meeting Resolutions Remuneration Medincell
BRIEF published on 07/30/2025 at 14:34, 9 months 2 days ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
PRESS RELEASE published on 07/30/2025 at 14:29, 9 months 2 days ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 9 months 2 days ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
PRESS RELEASE published on 07/30/2025 at 13:42, 9 months 2 days ago Inside Information / Other news releases Medincell's partner Teva increases 2025 revenue outlook for UZEDY® to $190–$200M, plans olanzapine LAI submission. Company's innovative treatments aim to improve medicine accessibility Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 07/30/2025 at 11:43, 9 months 2 days ago Medincell Releases 2024-25 Universal Registration Document Shareholders Governance Financial Report CSR Medincell
PRESS RELEASE published on 07/30/2025 at 11:38, 9 months 2 days ago Annual financial and audit reports / Terms of availability of the annual financial report Medincell announces availability of its 2024-25 Universal Registration Document, including financial and CSR reports. Innovative treatments developed aim to improve effectiveness of medicines Financial Reports Universal Registration Document CSR Innovative Treatments Medincell
Published on 05/02/2026 at 00:00, 22 minutes ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 22 minutes ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 1 hour 52 minutes ago Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 1 hour 52 minutes ago Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 1 hour 52 minutes ago Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.
Published on 05/01/2026 at 19:23, 4 hours 58 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 6 hours 36 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 7 hours ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 4 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 5 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 5 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 6 hours ago Minutes of the Combined General Meeting held on April 30, 2026
